The companies said they plan to develop a number of tests, beginning with a CTC-based PD-L1 assay that measures both RNA and protein expression.
The deal covers IncellDx's portfolio of immune-oncology and oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells and immune cell subtypes.
The two companies intend to develop and commercialize several cancer and NIPT assays using a combination of their technologies.
The deal covers IncellDx's single-cell immune-oncology and oncology diagnostic products including its single-cell PD-L1 assay.
The companies will study the combination of their respective technologies for predicting patient responses to metastatic lung cancer immunotherapy.
The kit uses a proprietary non-enzymatic method to prepare intact, single-cell suspensions from tissue in less than 10 minutes.
Single-cell RNA sequencing on thousands of tumor and surrounding cells from 19 melanoma samples revealed subsets of cells with apparent resistance potential.
IncellDx's investigational molecular assay used to quantify HPV E6/E7 mRNA in single cells has been optimized to run on Beckman Coulter's CytoFlex flow cytometry system.
The partners will couple Claremont BioSolutions' enzyme-free tissue homogenization technology with IncellDx's reagents.
IncellDx said this week that it has hired Christine Meda as chief business officer.
University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.
A new study of a β-thalassemia gene therapy appears promising, according to NPR.
Futurism writes that gene doping could be the next generation of cheating in sports.
In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.